Slide 1: Alligator Bioscience AB (publ)
ALLIGATOR BIOSCIENCE AB (PUBL) SEPTEMBER 2020 A REVOLUTION FOR LIFE 1
Slide 2: Disclaimer
Disclaimer FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that provide Alligator’s expectations or forecasts of future events such as new product developments, regulatory approvals and financial performance. Such forward looking statements are subject to risks, unce
Slide 3: Strong clinical immuno-oncology pipeline
Strong clinical immuno-oncology pipeline 3
Slide 4: Planned clinical readouts through 2022
Planned clinical readouts through 2022 ✓ Interim safety data readout for Phase I ATOR-1015 study (Q2 2020) 2020 ✓ Interim readout ATOR-1017 (Q3 2020) ❑ Readout for Phase I ATOR-1015 study (Q4 2020) ❑ Readout for Phase I ATOR-1017 study (H1 2021) 2021 ❑ Interim efficacy readout Phase II mitazalimab (
Slide 5: ATOR-1017: Designed for optimal efficacy and safety
ATOR-1017: Designed for optimal efficacy and safety A tumor-directed 4-1BB antibody Phase I Phase II Phase I readout: (DC) H1 2021E • Superior safety/efficacy profile vs other 4-1BB Best-in-class antibodies Unique • Unique 4-1BB domain design • IgG4 for tumor-directed effect > Activates 4-1BB expres
Slide 6: ATOR-1017: The optimal 4-1BB mAb
ATOR-1017: The optimal 4-1BB mAb ATOR-1017 was designed to overcome limitations observed with other 4-1BB antibodies Toxicity issues * Good efficacy Poor efficacy MTD ~ 0.1 mg/kg Good tolerability Well tolerated MTD≥10 mg/kg *Clinical development with urelumab was discontinued in phase II, due to li
Slide 7: ATOR-1017: Phase I interim readout
ATOR-1017: Phase I interim readout Encouraging safety profile > Dose-escalation ongoing, 40 mg flat dose has been cleared, next dose is 100 mg > 7 patients have been dosed and all are still on-study > Few drug related adverse events have been observed and all were mild or moderate (grade 1 or 2). Pa
Slide 8: ATOR-1017: Clinical development plan
ATOR-1017: Clinical development plan > Phase I open-label dose escalation study ongoing with safety data readout H1 2021E > Expected to enrol up to 50 patients with metastatic cancer at three Swedish clinics > Patients will be receiving ATOR-1017 every 3 weeks > Primary endpoints: safety & tolerabil
Slide 9: ATOR-1015: First-in-class tumor-localizing CTLA-4 x OX40 bispecific
ATOR-1015: First-in-class tumor-localizing CTLA-4 x OX40 bispecific A safer and more efficacious CTLA-4 targeting antibody Clinical opportunity Phase I started in March 2019. Currently Clinical Status evaluating doses of 12 mg/kg Tumor Clinical Efficacy readout Phase Ib mono study Tumor killing Deve
Slide 10: ATOR-1015: Supportive interim Phase I data at AACR/ASCO
ATOR-1015: Supportive interim Phase I data at AACR/ASCO > Cancer types: > Colorectal cancer (n=9) > Uveal melanoma (n=2) > Pancreatic cancer (n=2) > Ovarian cancer (n=2) > Cholangiocarcinoma, Gastric cancer, Cutaneous melanoma, Gallbladder cancer, Cervix cancer, Non small cell lung cancer (n=1 for e
Slide 11: ATOR-1015: Clinical development path
ATOR-1015: Clinical development path > Phase I safety ongoing, readout at medical conference in Q4 2020E > Phase Ib expansion study to start H1 2021E in melanoma, preliminary efficacy readout H1 2022E > Phase II combination study with anti-PD-1 in melanoma to start upon demonstration of single agent
Slide 12: Mitazalimab: Phase II ready CD40 antibody
Mitazalimab: Phase II ready CD40 antibody Unleashing the power of dendritic cells in IO Phase I complete Phase II/III, pancreatic cancer T cell Other indications: renal, H&N, bladder, lymphoma (DC) Tumor cell Clinical status Phase II ready CD40 agonist antibody Preclinical and clinical data package
Slide 13: Pancreatic cancer: clinical validation for CD40
Pancreatic cancer: clinical validation for CD40 CD40 increases cold tumors’ response rates Overall response rate (ORR) NP=nab-paclitaxel 60 60 60 40 40 40 20 20 20 0 0 0 1 1 40 em em D PD D +P G G +C + P+ em 40 em N G D G P+ +C P+ N em N Wainberg et al J Clin G Van Hoff et al O´Hara et al AACR, P+ N
Slide 14: OPTIMIZE-1: Mitazalimab in Pancreatic Cancer
OPTIMIZE-1: Mitazalimab in Pancreatic Cancer Establish safety and efficacy with Folfirinox Dosing regimen: Folfirinox 2 days before mitazalimab > Run-in part to demonstrate safety of mitazalimab in combination with standard of care > Expansion at selected dose (RP2D) with an additional 20 patients f
Slide 15: Mitazalimab: Clinical development path
Mitazalimab: Clinical development path > Current status: Phase I completed, Phase II ready > Phase II combination with chemotherapy, mFOLFIRINOX, in pancreatic cancer with planned CTA Q4 2020. PD-1 to be added upon efficacy response. > Interim readout H2 2021E > Efficacy readout, H2 2022 2020 2021 2
Slide 16: Investment highlights
Investment highlights 1 Advanced immuno-oncology company with an innovative technology platform that has produced 4 clinical-stage programs to date 2 ATOR-1017: best-in-class tumor-directed 4-1BB antibody ATOR-1015: first-in-class tumor-localizing antibody with 7e3 3 potential to replace current CTL
Slide 17: We fight cancer through the immune system
We fight cancer through the immune system A revolution for life 17